Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Replidyne has announced the restructuring of its operations reducing its current employee headcount by approximately 80% to 5 employees in actions that are scheduled to take place during September and October 2008.
Subscribe to our email newsletter
As a result of these actions Replidyne will suspend further development activities of REP3123, its investigational agent for the treatment of Clostridium difficile bacteria and C difficile infection, and novel anti-infective compounds based on its DNA replication inhibition technology.
Following completion of the restructuring actions, the company will limit its activities to completing its review of previously announced strategic alternatives.
The company estimates that it will incur $3.1 million of costs related to the restructuring of its operations comprised of $1.6 million for employee severance benefits, $0.8 million for lease payments in excess of expected sub-lease income and $0.7 million of non-cash expense for the write down of impaired fixed assets.
Kenneth Collins, president and CEO of Replidyne, said: “The process we are conducting involves a number of alternatives including merger or acquisition of the company together with the possible sale of our C difficile and DNA replication inhibition programs. While the process is ongoing, we are encouraged by our progress to date.”